Research News for October 2009
-
Researchers Question Value of Regular Screening Mammograms
A new study questions the value of regular screening mammograms; Breastcancer.org continues to believe the current recommendations make sense.
-
Women Who Choose Mastectomy Have Good Reasons for Choice
While greater numbers of women are choosing mastectomy instead of lumpectomy followed by radiation therapy to treat early-stage breast cancer, research suggests that these women have good reasons for their choice.
-
Radiation Therapy During, After Surgery Offer Same Cosmetic Results
Early results show that intraoperative radiation therapy and traditional external beam radiation therapy offer similar cosmetic results.
-
Three Types of Partial Breast Irradiation Have Similar Outcomes
Research shows that three alternatives to traditional external beam radiation therapy are all equally effective at lowering the risk of recurrence and offer the same benefits as traditional radiation therapy.
-
Younger Women More Likely to Have DCIS Recurrence
A new study suggests that younger women (under 45) who have lumpectomy and radiation therapy to treat DCIS are more likely to have the breast cancer come back (recurrence) compared to older women who had the same treatment.
-
Breast Cancer Diagnosed Earlier in Families with Abnormal Gene
The age at which breast cancer is being diagnosed in families with an abnormal breast cancer gene seems to be getting younger, according to a new study.
-
Abnormal Cells Found in 10% of Women Having Breast Reduction Surgery
A new study found that nearly 10% of 444 women who had surgery to reduce the size of their breasts had abnormal looking cells in the breast tissue that was removed.
-
Tween Girls Have Breast Cancer Fears and Misunderstand Risk
A study done by Dr. Marisa Weiss, president and founder of Breastcancer.org, found that teen and pre-teen ("tween") girls have breast cancer fears and misunderstand the risk of breast cancer for themselves and their mothers.
-
Herceptin Helps Treat Early-Stage, HER2-Positive Cancers
New research shows that Herceptin (chemical name: trastuzumab) offers benefits to women diagnosed with HER2-positive, early-stage breast cancer with a low risk of recurrence.
-
Women at Risk for Heart Problems After Breast Cancer Treatment
A small study shows that the risk of a serious heart problem, such as a stroke or heart attack, often is the same or greater than the risk of breast cancer recurrence.
